---
schema_version: "secwatch.filing_event.v1"
accession: "0001390478-22-000030"
form_type: "8-K"
ticker: "SLS"
cik: "0001390478"
company_name: "SELLAS Life Sciences Group, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T19:46:45.048124+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# SELLAS revises REGAL trial SAP; observed OS ~2-fold longer, enrollment to 125-140

## Summary
- Pooled blinded data shows overall survival ~2-fold longer than original protocol assumption; interim analysis reduced to 60 events, final to 80.
- Enrollment target increased from 116 to 125-140 patients; partner 3D Medicines to add ~20 patients from China.
- Milestone payments from 3DMed expected in H1 2023; potential for earlier China market entry if REGAL meets endpoints.
- Q3 2022 net loss $7.0M ($0.34 per share); cash and equivalents $21.3M as of Sep 30, 2022.
- Company hosting virtual investor event on REGAL update at 8:30 a.m. ET today.

## SEC filing metadata
- accession: 0001390478-22-000030
- form_type: 8-K
- ticker: SLS
- cik: 0001390478
- company_name: SELLAS Life Sciences Group, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1390478/000139047822000030/0001390478-22-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1390478/000139047822000030/sls-20221114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001390478-22-000030
- JSON: https://secwatch.observer/filing/0001390478-22-000030.json
- Plain text: https://secwatch.observer/filing/0001390478-22-000030.txt

## Key facts
- Earnings Releases
  SELLAS Life Sciences Group, Inc. reported quarter ended September 30, 2022 results: net income Net loss was $7.0 million for the third quarter of 2022, or a basic and diluted loss per share of $0.34.
  - Period: quarter ended September 30, 2022
  - Net income: Net loss was $7.0 million for the third quarter of 2022, or a basic and diluted loss per share of $0.34
  - Result: reported results
  source text: On November 14, 2022, SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended September 30, 2022 and providing a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1390478/000139047822000030/0001390478-22-000030-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.